Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Janone Inc JAN

Industrials
JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. The Company’s drug candidate is a treatment for Peripheral Artery Disease, a condition that can cause severe pain and affects over 8.5 million people in the United States. The Company operates through the Biotechnology segment, which is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.


NDAQ:JAN - Post by User

Janone Inc
<< Previous
 Bullboard Posts
User Avatar Image
(83)
•••
Post by whytestockson Apr 16, 2024 4:30pm
19 Views
Post# 35992323

JanOne Inc. (NASDAQ: JAN) Sets New 52-Week High in Tuesday S

JanOne Inc. (NASDAQ: JAN) Sets New 52-Week High in Tuesday S
JUST IN: $JAN JanOne Inc. (NASDAQ: JAN) Sets New 52-Week High in Tuesday SessionShares of JanOne Inc. (NASDAQ: JAN) traded at a new 52-week high today and are currently trading at $3.29. So far today, approximately 102.47k shares have been exchanged, as compared to an average 30-day volume of 135.62k shares. JanOne Inc., a clinical-stage biopharmaceutical company, focuse...JAN - JanOne Inc. (NASDAQ: JAN) Sets New 52-Week High in Tuesday Session

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities